Insmed Incorporated
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- William H. Lewis
- Full Time Employees
- 1,664
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 700 US Highway 202/206 Bridgewater NJ United States of America 08807
- IPO Date
- Jun 1, 2000
- CIK
- 0001104506
- Website
- insmed.com
- Similar Companies
- Business
- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company founded in 1988 and headquartered in Bridgewater, New Jersey, focuses on rare diseases with investigational and approved therapies in pulmonary, inflammatory, and other serious conditions; its approved products include ARIKAYCE (amikacin liposome inhalation suspension) for Mycobacterium avium complex lung disease in adults with limited treatment options and BRINSUPRI (brensocatib), a first-in-class neutrophil elastase inhibitor for non-cystic fibrosis bronchiectasis; the company advances a pipeline encompassing TPIP for pulmonary arterial hypertension, INS1201, and preclinical programs in gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, serving patients primarily through clinical trials and commercial launches targeting chronic lung diseases. Insmed operates 9 corporate offices and 4 global research sites across the United States, Europe, Japan, and other regions, with over 1,500 employees as of mid-2025. Recent developments include FDA approval of BRINSUPRI in 2025 and its subsequent European Union approval, topline results from the Phase 2b pulmonary arterial hypertension study and Phase 3 ASPEN study in 2024-2025, the opening of a new research lab in Cambridge, UK, a proposed $650 million public offering of common stock in June 2025, raised full-year 2025 ARIKAYCE revenue guidance to $420-430 million, and repeated recognition as the No. 1 biopharma employer by Science magazine.
Insmed Tops Q2 Earnings Estimates, Stock Soars 34% on Brinsupri Uptake
Insmed Q2 Earnings Call Highlights
Insmed Incorporated (INSM) Q2 2026 Earnings Call Transcript
Insmed (INSM) Reports Q2 Earnings: What Key Metrics Have to Say
Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates
Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update
Insmed, Inc. $INSM Stock Holdings Reduced by Bank of Nova Scotia
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026
Andra AP fonden Buys 41,670 Shares of Insmed, Inc. $INSM
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Adobe, Datadog, Five Below, Fortinet, Gilead Sciences, Goldman Sachs, Microsoft, Salesforce, and More
Billionaire Investor Stanley Druckenmiller's Top 5 Picks: Worth Buying Today?
Bank of New York Mellon Corp Cuts Stake in Insmed, Inc. $INSM
Insmed Incorporated (INSM) Discusses 12-Month Results From Ongoing TPIP Open-Label Extension Study in PAH Patients Transcript
Insmed Sees Sustained Gains With Inhaled Drug for Stressed Heart Functioning
Insmed's TPIP Shows Durable PAH Benefits in 12-Month Study
Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension
Carillon Eagle Mid Cap Growth Fund Q2 2026 Portfolio Review
EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis